Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of chidamide + anti-PD-(L)1 antibody + gemcitabine-based chemotherapy for first-line advanced pancreatic cancer
ChiCTR2200055523Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and gemcitabine in pancreatic cancer (PC), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Objective response rate and Safety. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
tucidinostatgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2200055523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055523.